MHLW Orders Label Revision for Xeljanz to Add “Venous Thromboembolism” to ADR List

August 23, 2019
The Pharmaceutical Safety Division of the Ministry of Health, Labor and Welfare (MHLW) ordered on August 22 revisions to the package insert for a batch of drugs including Pfizer’s JAK inhibitor Xeljanz (tofacitinib). “Venous thromboembolism (VTE)” will be added to...read more